New Ventures

How we work

We employ a unique in-house model to refine and de-risk commercially viable new venture opportunities at UHN. Our team of seasoned industry business development experts, IP specialists and legal counsel, in concert with our Entrepreneurs-in-Residence, work on nurturing newly-founded companies – maximizing patient impact around the world.

Our new ventures contain robust IP portfolios, most-often equipped with long-term protection.

MORE on our unique approach

Many of our more mature companies are open to later-stage investments.

view Companies


Treating atrial fibrillation with conductive biomaterials

Medly Therapeutics

Digital health platform transforming care for heart failure /chronic conditions

Curait Medical

AI-driven quality assurance platform for radiation oncology


Biologic in development for CNS disorders with applications in ophthalmology


Nanomedicine therapeutic opportunity with new generation of multi-capacity photosensitizers (porphysomes)


Preventing cardiotoxicity associated with doxorubicin


Small Molecule Therapeutics for Rare and Neurodegenerative Diseases